Axiom Therapeutics

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

No changes recorded yet. Missing observations do not mean the company has not changed.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

1. September 2024 – July 2025 · 3 captures · latest observed messagingUnlocking the Future of Drug Discovery

   Axiom Therapeutics is developing the next generation of small molecule therapeutics, powered by our machine learning platform.

   This wording observed 10 July 2025.

   archived page
   Inspect 3 captures in this group

   • 23 September 2024 · Unlocking the Future of Drug Discovery archived page
   • 15 January 2025 · Unlocking the Future of Drug Discovery archived page
   • 10 July 2025 · Unlocking the Future of Drug Discovery archived page

Companies in the same space

Competitors picked by an AI model from the funded startups with the most similar descriptions, judged on those descriptions only. A reading, not a verified market map.

• Frontier Medicines frontiermeds.comDirect competitorBoth use AI and covalent chemistry platforms to design covalent small‑molecule drugs for difficult oncology targets.
• Vividion Therapeutics vividion.comDirect competitorBoth focus on covalent chemistry platforms to discover covalent small‑molecule oncology drugs for hard‑to‑target proteins.
• PharmCADD pharmcadd.comPartial overlapBoth license AI‑driven in‑silico drug design platforms to pharma and biotech for small‑molecule discovery.
• Numerion Labs (formerly Atomwise) numerionlabs.aiPartial overlapBoth provide AI platforms and collaborations for small‑molecule drug discovery using deep‑learning‑based design.
• Atomwise atomwise.comPartial overlapBoth use AI for structure‑based small‑molecule design and partner with pharma to advance preclinical candidates.
• Isomorphic Labs isomorphiclabs.comPartial overlapBoth run AI‑first platforms to design new small‑molecule therapeutics and pursue partnerships with pharma and biotech.